Last reviewed · How we verify
CETRIMONIUM
CETRIMONIUM is a cetrimonium drug. It is currently in Phase 2 development.
CETRIMONIUM works by interacting with Dynamin-1 to modulate cellular processes.
CETRIMONIUM is a small molecule drug that targets Dynamin-1, a protein involved in cellular processes. It belongs to the cetrimonium class and its exact commercial status is unknown. The drug's mechanism of action and approved indications are not specified. Further information on its pharmacokinetic properties, such as half-life and bioavailability, is also lacking. As a result, its clinical use and safety profile remain unclear.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CETRIMONIUM |
|---|---|
| Drug class | cetrimonium |
| Target | Dynamin-1 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine Dynamin-1 as a key that helps cells break down and recycle their components. CETRIMONIUM is like a lock that binds to this key, altering the way cells function. This interaction can potentially affect various cellular processes, but the exact effects are still unknown.
Approved indications
Common side effects
Key clinical trials
- Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG - Second Trial (PHASE2)
- IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers (NA)
- Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II) (PHASE3)
- Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG (PHASE2)
- Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU) (PHASE3)
- Molecular Detection Of Efflux Pump and Virulence Factors Genes in Pseudomonas Aeruginosa
- Suprapubic Aspiration Versus Urinary Catheterization In Neonates. (NA)
- Single-centre Study to Investigate Safety and Efficacy of Tri-Solfen in Wound Debridement (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CETRIMONIUM CI brief — competitive landscape report
- CETRIMONIUM updates RSS · CI watch RSS
Frequently asked questions about CETRIMONIUM
What is CETRIMONIUM?
How does CETRIMONIUM work?
What drug class is CETRIMONIUM in?
What development phase is CETRIMONIUM in?
What does CETRIMONIUM target?
Related
- Drug class: All cetrimonium drugs
- Target: All drugs targeting Dynamin-1
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing